Phase 3 Alogliptin Pediatric Study
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 152 participants.
Also called NCT02856113
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 152 participants
- Sponsor
- Registry
-
NCT02856113 -
U1111-1174-1923 -
2015-000208-25
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Brazil, Israel, Italy, Mexico, Poland, Russia
- Registry status
- Completed
Technical summary
Registry record NCT02856113. Randomized; quadruple masking; primary purpose treatment. Start 2016-10-14 (actual); primary completion 2021-08-06 (actual). Results posted on 2022-10-19.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Phase 3 Alogliptin Pediatric Study
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Alogliptin Benzoate
- Intervention (Drug)
- Placebo
- Lead sponsor
- Takeda
- Collaborator
- Takeda Development Center Americas, Inc.
Record details
- Record id
cardio:ct-nct02856113- Content hash
21b47fcda0d0335548c4eb13d159aef0addc6a43d942348f03d2850b9c6c95e3